TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05966181

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: experimental group
Description: Experimental Group-Repetitive Simulation~* First simulation application; It will be done in groups of four with a total of 5 groups (n=20). In each scenario, one student in the group will participate in the role of nurse and three other students will participate as audience. Four students in each group will take part in a standard patient simulation consisting of four different scenarios.~* Second simulation application; It will be carried out with the students in the experimental group about 3-4 weeks after the first simulation. Each student will use one new scenario alone in the second simulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experimental group
Description: Experimental Group-Repetitive Simulation~* First simulation application; It will be done in groups of four with a total of 5 groups (n=20). In each scenario, one student in the group will participate in the role of nurse and three other students will participate as audience. Four students in each group will take part in a standard patient simulation consisting of four different scenarios.~* Second simulation application; It will be carried out with the students in the experimental group about 3-4 weeks after the first simulation. Each student will use one new scenario alone in the second simulation.
Study: NCT04866563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-8, Part 1 of the study
Description: orally disintegrating tablets, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-8, Part 1 of the study
Description: orally disintegrating tablets, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, Part 1 of the study
Description: orally disintegrating tablets, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, Part 1 of the study
Description: orally disintegrating tablets, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-8, Part 2 of the study
Description: orally disintegrating tablets, TID
Study: NCT06492616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Administered as oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Administered as oral tablets
Study: NCT05208515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: independent obsteric operating center
Description: send emergency cesarean section needing women from labor room to independent obstetric operating center
Study: NCT06492616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Administered as oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Administered as oral tablets
Study: NCT06326905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPABLE Transplant- Open Label Pilot
Description: As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW).~Adaptations targeting those currently KT inactive will be made on a per-client basis as part of the open-label pilot. We will further refine and develop the intervention by receiving feedback from the open label pilot participants and CAPABLE clinicians who implemented the pilot to gain their perspective of the acceptability and feasibility of implementing the CAPABLE-Transplant intervention. Based on this feedback, the study team will have developed an adapted iteration of the prototype.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPABLE Transplant- Randomized Control Trial
Description: As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAPABLE Transplant- Randomized Control Trial
Description: As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
Study: NCT04629547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg
Description: Suvorexant 20mg will be taken nightly for 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken nightly for 24 months.
Study: NCT05206942

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Description: Power Doppler measurements will be made using a portable Siemens S2000 or S3000 ultrasound scanner

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Long Ensemble Angular-coherence Doppler [LEAD] ultrasound
Description: Long Ensemble Angular-coherence Doppler measurements will be made using a Verasonics Vantage 256 scanner

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Description: Contrast-enhanced ultrasound measurements will be made using Lumason IV contrast injection followed by an injection of normal saline
Study: NCT05139810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donidalorsen
Description: Donidalorsen will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donidalorsen
Description: Donidalorsen will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Donidalorsen-matching placebo will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Donidalorsen-matching placebo will be administered by SC injection.
Study: NCT06273436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H.E.A.R. for Mamas
Description: H.E.A.R. for Mamas is a patient and provider informed, multicomponent intervention that uses simple text/phone-based screenings to systematically and frequently monitor women for postpartum complications, chronic conditions and SDoH (Social Determinants of Health) and provides patients with immediate feedback and recommendations based on their screenings.
Study: NCT04965246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The physical activity program will focus on increasing physical activity, starting with a target of 100 minutes per week. The session durations will build over time to 150 minutes per week. Participants will be instructed to walk, or engage in other forms of light-intensity physical activity to achieve these goals. Participants will be instructed on the use of the ratings of perceived exertion scale (6-20). As the participants' health and fitness status improves, frequency, intensity, and session duration will be modified accordingly during weekly support calls. As participants will enter the study engaging in varying levels of physical activity, goals will be responsive to the most recent week's achieved minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participants in the usual care group will receive no intervention
Study: NCT06558149

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Those whose opioids were adjusted according to hemodynamic parameters
Description: Patient who will be adjusted according to hemodynamic parameter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Those whose opioids were adjusted according to NOL monitoring
Description: Patient who will be adjusted according to NOL monitoring
Study: NCT05418244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaled Isopropyl Alcohol
Description: Isopropyl alcohol pad (Covidien Webcol 2 ply prep pads, saturated with 70% isopropyl alcohol) held 1-2 cm under the subject's nares

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Ondansetron
Description: 4 mg oral disintegrating ondansetron tablet once

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: Normal saline pad (Hygea sterile saline wipe) held 1-2 cm under the subject's nares
Study: NCT06505746

Intervention type: OTHER
Intervention: No intervention
Description: No investigational drug will be administered to participants in this study.
Study: NCT05466799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX chemotherapy
Description: Standard Of Care Chemotherapy regimen for treatment of Locally Advanced Pancreatic cancer
Study: NCT05179187

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Movement task
Description: Computer task with experimental conditions manipulating sensory and motivation cues for movement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement task
Description: Computer task with experimental conditions manipulating sensory and motivation cues for movement.
Study: NCT05623436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing students will be trained through virtual reality.
Description: Nursing students will be trained through virtual reality.
Study: NCT05466799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX chemotherapy
Description: Standard Of Care Chemotherapy regimen for treatment of Locally Advanced Pancreatic cancer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoSil™
Description: Implantation of OncoSil 32P microparticles into the Pancreatic Tumour under EUS guidance
Study: NCT04630496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Electronic activity tracker
Study: NCT06379971

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pregnant women are instructed to take the capsules twice per day, 4 placebo capsules at breakfast and 4 placebo capsules at dinner. Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choline
Description: Pregnant women are instructed to take the capsules twice per day, 4 900mg phosphatidylcholine capsules at breakfast and 4 capsules at dinner. Increased awareness Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.
Study: NCT06175832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elonva®
Description: Single injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puregon®
Description: Multiple injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Puregon®
Description: Multiple injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orgalutran®
Description: Multiple injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonapeptyl®
Description: Double injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonapeptyl®
Description: Double injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerazette®
Description: Oral tablet
Study: NCT05626257

Intervention type: OTHER
Intervention: Xolair
Description: There is no treatment allocation. Patients administered Xolair by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT06348199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB27
Description: Will be administered intravenously at a fixed dose of 200 mg every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keytruda
Description: Will be administered intravenously at a fixed dose of 200 mg every 3 weeks
Study: NCT06488248

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy (ETV)
Description: The procedure is performed using an endoscope (LOTTA® system, Karl Storz Endoscopes, Germany; Minop®, BBraun, Tuttlingen, Germany or equivalent). The intervention is carried out under general anesthesia, with the procedure typically lasting around 60 minutes.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ventriculoperitoneal shunt (VPS)
Description: The procedure entails the insertion of a catheter into both the ventricular system and the peritoneal cavity, connected to a programmable valve that regulates cerebrospinal fluid flow. The choice of programmable valve (Codman Hakim or Codman Certas Programmable Valves, Integra, Plainsboro, USA; Strata valve, Medtronic, Minneapolis, USA; Sophysa, Orsay, France; Miethke proGAV, Aesculap, Tuttlingen, Germany) is at the surgeon's discretion. The preoperative valve setting is preset to a pressure level between 85 - 135 mmH2O. The VPS procedure is conducted under general anesthesia and typically lasts approximately 90-120 minutes.
Study: NCT06382610

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin will be administered in three different forms

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin will be administered in three different forms

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin will be administered in three different forms
Study: NCT06081127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MOve-ABC
Description: The intervention is called Moving On After Breast Cancer (MOve-ABC) and includes:~1. Three in-person visits for clinical measurements~2. Enhanced usual care (EUC)~3. Pre-hab ((Pre-Treatment) PT evaluation and individualized home therapeutic exercise prescription with safe progressions).~4. Teach Back (HEP, post-op movement precautions)~5. Self-management education with reinforcement check-ins via text messaging and phone calls at regular intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: All patients will receive EUC. However, half of our sample will have only EUC consisting of~1. Three in-person visits for clinical measurements~2. Planned oncology treatment (surgery, chemotherapy, radiation)~3. Nursing education on surgical site and drain care, post-operative movement precautions, pain management~4. If needed, laboratory and radiological testing to rule out disorders that interfere with treatment outcomes~5. Monthly monitoring with Patient-Reported Outcomes Measurement Information System - Physical Function (PROMIS-PF) surveys beginning at baseline with alerts from scores = or \< 45 (indicating moderate or severe impairment) for physical therapy referral
Study: NCT04515784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Aid Reduction Treatment for PTSD
Description: START-PTSD includes many of the key elements found in empirically supported treatments for PTSD including: a) psychoeducation regarding the development and maintenance of PTSD; and b) exposure to internal sensations and external situations that are connected to one's fear/distress response via identification and elimination of safety aids. Known safety aids to be covered include: cognitive avoidance (e.g., using mental distractions to avoid trauma-related images); situational avoidance (e.g., avoiding crowded market places); checking behaviors (e.g., checking doors, windows, locks, and perimeters more often than necessary); reassurance seeking (e.g., excessively watching the news); other compulsive behaviors (e.g., checking the location of exits); use of companions (e.g., relying on someone to attend a social gathering); and use of alcohol and certain substances (e.g., consuming alcohol to reduce anxiety).
Study: NCT05809167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEN+AZA+Modified BUCY
Description: Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days.
Study: NCT04937114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Barbed suture
Description: Experimental: Wound will be closed using unidirectional barbed sutures in muco-gingival surgeries Active Comparator: Wound will be closed using conventional sutures in muco-gingival surgeries

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Barbed suture
Description: Experimental: Wound will be closed using unidirectional barbed sutures in muco-gingival surgeries Active Comparator: Wound will be closed using conventional sutures in muco-gingival surgeries
Study: NCT05393518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety-induced task
Description: Subjects will be asked to describe their most anxious thoughts and write each of them in a detailed scenario. The scenarios will be based on the answers to the Worry and Anxiety Questionnaire, in order to validate the procedure by a standardized examination. During the task, the scenarios will be successively presented to the subjects, on a digital computer medium in written and oral format. Subjects will be asked to actively focus on these negative thoughts with maximum concern, without seeking to control their emotions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anxiety-induced task
Description: Subjects will be asked to describe their most anxious thoughts and write each of them in a detailed scenario. The scenarios will be based on the answers to the Worry and Anxiety Questionnaire, in order to validate the procedure by a standardized examination. During the task, the scenarios will be successively presented to the subjects, on a digital computer medium in written and oral format. Subjects will be asked to actively focus on these negative thoughts with maximum concern, without seeking to control their emotions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric assessment
Description: Screening for depression and anxiety

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychiatric assessment
Description: Screening for depression and anxiety
Study: NCT05013437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evomela
Description: 16 mg/m\^2 Evomela administered one time via a central line
Study: NCT04866563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-8, Part 2 of the study
Description: orally disintegrating tablets, TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, Part 2 of the study
Description: orally disintegrating tablets, TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, Part 2 of the study
Description: orally disintegrating tablets, TID
Study: NCT05013437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next Generation Sequencing
Description: Next Generation Sequencing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Description: 10mg once intravenous (IV) within 30 minutes before Evomela

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 650 mg once orally within 30 minutes before Evomela

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 50 mg once intravenously within 30 minutes before Evomela
Study: NCT04872166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-A51
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-A51
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-A51
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-A51
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-A51
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-A51
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-A51
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-A51
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.
Study: NCT05609864

Intervention type: OTHER
Intervention: Quantification of injectable drugs wastage
Description: Drugs are prescribed at discretion of physicians. For each patient who have anesthesia in the operating room, all labelled syringes having contained drugs (name + dilution) are collected and analyzed.
Study: NCT06482853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be used as the placebo comparator.
Study: NCT06062043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief ACT with CPP Education Treatment
Description: The Brief ACT with CPP Education treatment provides women veterans with new ways of responding to difficult thoughts and emotions related to pain while also encouraging them to engage in meaningful life activities. The CPP educational component includes information about pathology, risk factors, health outcomes, and treatment that are specific to women's biological and reproductive functioning. Treatment content has been further tailored to reflect the cultural experiences of women veterans (including discussions on the interplay between military culture, perceived social norms, and gender role expectations).